DB:ELN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Elanix Biotechnologies AG, a tissue regeneration company, develops and commercializes products for acute wound care, dermatological, and gynecological applications, and provides cell technology services. More Details


Snowflake Analysis

Excellent balance sheet with weak fundamentals.

Share Price & News

How has Elanix Biotechnologies's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ELN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.8%

ELN

5.3%

DE Biotechs

0.2%

DE Market


1 Year Return

-15.6%

ELN

5.5%

DE Biotechs

6.6%

DE Market

Return vs Industry: ELN underperformed the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: ELN underperformed the German Market which returned 6.6% over the past year.


Shareholder returns

ELNIndustryMarket
7 Day-5.8%5.3%0.2%
30 Day-13.9%2.8%2.1%
90 Day106.2%7.8%5.6%
1 Year-15.6%-15.6%5.7%5.5%9.1%6.6%
3 Year-82.5%-82.8%20.5%19.3%6.8%-1.8%
5 Year-52.8%-55.5%49.5%47.1%38.9%20.1%

Price Volatility Vs. Market

How volatile is Elanix Biotechnologies's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Elanix Biotechnologies undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Elanix Biotechnologies is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Elanix Biotechnologies has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Elanix Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

61.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Elanix Biotechnologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine Elanix Biotechnologies's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • Elanix Biotechnologies competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Pharmaceuticals & Biotech industry.

Past Performance

How has Elanix Biotechnologies performed over the past 5 years?

18.9%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if ELN has high quality earnings.

Growing Profit Margin: Insufficient data to determine if ELN's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ELN's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare ELN's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if ELN's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: ELN has a negative Return on Equity (0%), as it is currently unprofitable.


Next Steps

Financial Health

How is Elanix Biotechnologies's financial position?


In this section we usually analyse Elanix Biotechnologies's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Elanix Biotechnologies has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of ELN’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. Elanix Biotechnologies's cash and debt levels may be found in its annual reports archived here.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Elanix Biotechnologies's financial data was last updated here.
  • Explore more healthy companies in the Pharmaceuticals & Biotech industry.

Dividend

What is Elanix Biotechnologies's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ELN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ELN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ELN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ELN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ELN's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.6yrs

Average board tenure


CEO

Lee-Ann Laurent-Applegate

no data

Tenure

Prof. Lee-Ann Laurent-Applegate serves as Chief Executive Officer of Elanix Biotechnologies AG.


Board Members

NamePositionTenureCompensationOwnership
Anja Silling
Chairman of Supervisory Board1.42yrsno data12.85%
€ 929.6k
Marco Christen
Vice Chairman of Supervisory Board0.58yrno datano data
Yves Bonnard
Member of Supervisory Board0.58yrno datano data

0.6yrs

Average Tenure

Experienced Board: ELN's board of directors are not considered experienced ( 0.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Elanix Biotechnologies AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Elanix Biotechnologies AG
  • Ticker: ELN
  • Exchange: DB
  • Founded: 1966
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €7.232m
  • Shares outstanding: 8.08m
  • Website: https://www.elanixbiotechnologies.ch

Number of Employees


Location

  • Elanix Biotechnologies AG
  • Route de la Corniche 4
  • Biopole
  • Epalinges
  • Vaud
  • 1066
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ELNDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1998
ELNXTRA (XETRA Trading Platform)YesCommon StockDEEURNov 1998
0NQALSE (London Stock Exchange)YesCommon StockGBEURNov 1998
ELNJDB (Deutsche Boerse AG)NPV NEW SHARESDEEURAug 2018

Biography

Elanix Biotechnologies AG, a tissue regeneration company, develops and commercializes products for acute wound care, dermatological, and gynecological applications, and provides cell technology services. I ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/18 03:33
End of Day Share Price2020/09/17 00:00
Earnings2018/06/30
Annual Earnings2017/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.